Fabry disease, enzyme replacement therapy and the significance of antibody responses

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

(2010) Mariëlle J. van Breemen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C

(2010) G. GIANNELLI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

(2010) Darius Ghaderi et al.   NATURE BIOTECHNOLOGY

Successful oral tolerance induction in severe peanut allergy

(2009) A. T. Clark et al.   ALLERGY

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

(2009) Jean-Claude Lubanda et al.   GENETICS IN MEDICINE

Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry

(2009) Stephen Waldek et al.   GENETICS IN MEDICINE

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

(2009) Catharina Whybra et al.   GENETICS IN MEDICINE

Screening for Fabry disease in high-risk populations: a systematic review

(2009) G. E. Linthorst et al.   JOURNAL OF MEDICAL GENETICS

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

(2009) Priya S. Kishnani et al.   MOLECULAR GENETICS AND METABOLISM

Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria

(2009) Julia Kleinert et al.   TRANSPLANT INTERNATIONAL

The immunogenicity of therapeutic proteins and the fabry antibody standardization initiative

(2008) Huub Schellekens   CLINICAL THERAPEUTICS

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

(2008) David Bodensteiner et al.   GENETICS IN MEDICINE

Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta

(2008) Atul Mehta et al.   MOLECULAR GENETICS AND METABOLISM

Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3

(2008) Anouk C. Vedder et al.   MOLECULAR GENETICS AND METABOLISM

Reduced α-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

(2008) Toya Ohashi et al.   MOLECULAR GENETICS AND METABOLISM

A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease

(2008) Bernard Bénichou et al.   MOLECULAR GENETICS AND METABOLISM

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

(2008) Jinhai Wang et al.   NATURE BIOTECHNOLOGY

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

(2007) D A Hughes et al.   HEART